PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.
A study on live tissue cells is the first to reveal how channels that allow sodium to enter into breast cancer cells enable tumors to grow and spread. The discovery adds to evidence which suggests ...
Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...
South Korea’s SK Biopharmaceuticals Co. Ltd. and Shanghai-based Ignis Therapeutic Co. Ltd. signed a ₩804 billion (US$58 million) licensing deal on April 18, granting the latter global rights to a ...
New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in patients taking widely used rhythm-control medications such as flecainide, which ...
Inspired by the natural bonding between a class of potent local anesthetics called site-1 sodium channel blockers (S1SCBs) and peptide sequences on the sodium channel in the nerve cell membrane, ...
A novel, investigational NaV1.8 sodium channel blocker known as VX-548 reduced acute pain after abdominoplasty or bunionectomy at the highest dose, but not at lower doses, two phase II trials showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results